Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Danavorexton (TAK-925) in Adults With Obstructive Sleep Apnea

Phase 1

Completed

Conditions: Sleep Apnea

Interventions: Drug: Placebo
Drug: Danavorexton

First Posted Date: 2022-01-06

Last Posted Date: 2022-12-02

Lead Sponsor: Takeda

Target Recruit Count: 13

Registration Number: NCT05180890

Locations: 🇦🇺
Adelaide Institute for Sleep Health (AISH), Flinders University, Adelaide, Australia

A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

Phase 1

Active, not recruiting

Conditions: Kidney Disease
Glomerulonephritis

Interventions: Drug: Mezagitamab

First Posted Date: 2021-12-30

Last Posted Date: 2024-12-11

Lead Sponsor: Takeda

Target Recruit Count: 16

Registration Number: NCT05174221

Locations: 🇸🇬
National University Hospital- Singapore, Singapore, Singapore
🇦🇺
Core Research Group, Milton, Queensland, Australia
🇨🇳
Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China

and more 23 locations

A Study of TAK-103 in Adult with Solid Tumors

Phase 1

Active, not recruiting

Conditions: Solid Tumors

Interventions: Biological: TAK-103

First Posted Date: 2021-12-21

Last Posted Date: 2024-12-03

Lead Sponsor: Takeda

Target Recruit Count: 2

Registration Number: NCT05164666

Locations: 🇯🇵
Hyogo College of Medicine Hospital, Nishinomiya, Hyogo, Japan
🇯🇵
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome

Phase 3

Recruiting

Conditions: Dravet Syndrome (DS)
Lennox Gastaut Syndrome (LGS)

Interventions: Drug: Soticlestat

First Posted Date: 2021-12-20

Last Posted Date: 2024-02-21

Lead Sponsor: Takeda

Target Recruit Count: 400

Registration Number: NCT05163314

Locations: 🇺🇸
Pediatric Neurology PA, Winter Park, Florida, United States
🇨🇦
Hospital For Sick Children, Toronto, Ontario, Canada
🇺🇸
Clinical Integrative Research Center of Atlanta, Atlanta, Georgia, United States

and more 112 locations

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Phase 3

Recruiting

Conditions: Coagulation Disorder

Interventions: Drug: SOC 4F-PCC
Drug: TAK-330

First Posted Date: 2021-12-14

Last Posted Date: 2024-12-19

Lead Sponsor: Takeda

Target Recruit Count: 328

Registration Number: NCT05156983

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
University of California Davis Health System, Sacramento, California, United States
🇺🇸
University of Louisville School of Medicine, Louisville, Kentucky, United States

and more 45 locations

A Study to Improve the Awareness of Mucopolysaccharidosis Type II in Brazil

Completed

Conditions: Mucopolysaccharidosis (MPS)

Interventions: Other: No Intervention

First Posted Date: 2021-12-13

Last Posted Date: 2022-05-09

Lead Sponsor: Takeda

Target Recruit Count: 250

Registration Number: NCT05155488

Locations: 🇧🇷
Takeda Distribuidora Ltda, São Paulo, Brazil

A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis

Phase 2

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: NDI-034858
Other: Placebo

First Posted Date: 2021-12-10

Last Posted Date: 2024-05-31

Lead Sponsor: Takeda

Target Recruit Count: 305

Registration Number: NCT05153148

Locations: 🇵🇱
Nimbus site #XYZ, Wroclaw, Poland

A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)

Phase 3

Completed

Conditions: Primary Immunodeficiency Diseases (PID)

Interventions: Drug: TAK-771

First Posted Date: 2021-12-09

Last Posted Date: 2024-11-25

Lead Sponsor: Takeda

Target Recruit Count: 16

Registration Number: NCT05150340

Locations: 🇯🇵
Saitama Prefectual Children's Medical Center, Saitama, Japan
🇯🇵
Shizuoka Childrens Hospital, Shizuoka, Japan
🇯🇵
Nagoya University Hospital, Nagoya, Aichi, Japan

and more 9 locations

A Study With Lanadelumab in Persons With Hereditary Angioedema (HAE) in Poland

Active, not recruiting

Conditions: Hereditary Angioedema (HAE)

First Posted Date: 2021-12-07

Last Posted Date: 2024-07-29

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT05147181

Locations: 🇵🇱
Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego, Lublin, Lubelskie, Poland
🇵🇱
Szpital Uniwersytecki w Krakowie, Kraków, Małopolskie, Poland
🇵🇱
Kliniczny Szpital Wojewódzki nr 1 im. Fryderyka Chopina w Rzeszowie, Rzeszów, Podkarpackie, Poland

and more 11 locations

A Study of Relative Bioavailability of a New Formulation Compared With the Approved Formulation of rhPTH [1-84] and to Find Out Dose Linearity of the New Formulation in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: rhPTH(1-84)

First Posted Date: 2021-11-30

Last Posted Date: 2023-12-15

Lead Sponsor: Takeda

Target Recruit Count: 96

Registration Number: NCT05137730

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy